表紙
市場調査レポート

小細胞性肺癌:世界の治験動向

Small-Cell Lung Cancer Global Clinical Trials Review, H1, 2016

発行 GlobalData 商品コード 229163
出版日 ページ情報 英文 509 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
小細胞性肺癌:世界の治験動向 Small-Cell Lung Cancer Global Clinical Trials Review, H1, 2016
出版日: 2016年06月29日 ページ情報: 英文 509 Pages
概要

当レポートでは、小細胞性肺癌治療薬に関する治験の最新動向について分析し、疾患の概要をはじめ、地域および主要国における治験の状況、進捗状況別の治験データ、被験者の募集状況、有望なスポンサー、そして各企業・研究機関の治験プロファイルなどの情報を盛り込んでお届けします。

当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域の主要5ヶ国における治験件数
    • 欧州の主要5ヶ国における治験件数
    • 北米の主要国における治験件数
    • 中東・アフリカの主要国における治験件数
    • 中南米の主要5カ国における治験件数

G7諸国での治験件数:癌治療薬の治験における小細胞性肺癌の割合

G7諸国における段階別の治験件数

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:癌治療薬の治験における小細胞性肺癌の割合

E7諸国における段階別の治験件数

E7諸国での治験件数:進捗状況別

段階別の治験件数

  • 進行中の治験:段階別

進捗状況別の治験件数

治験の目標の達成状況

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

小細胞性肺癌治療薬の治験に携わっている主要企業

有望な薬剤

最新の治験ニュース

治験プロファイルの概要

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC3500CTIDB

GlobalData's clinical trial report, "Small-Cell Lung Cancer Global Clinical Trials Review, H1, 2016" provides an overview of Small-Cell Lung Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Small-Cell Lung Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Small-Cell Lung Cancer to Oncology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Small-Cell Lung Cancer to Oncology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Small-Cell Lung Cancer Therapeutics Clinical Trials
  • Prominent Drugs
    • Latest Clinical Trials News on Small-Cell Lung Cancer
      • Jun 06, 2016: Immunomedics Announces Sacituzumab Govitecan (IMMU-132) is Active in Patients With Previously-Treated Metastatic Small-Cell Lung Cancer
      • Jun 05, 2016: Results of Phase 1a/1b Study of AbbVies Investigational Medicine Rovalpituzumab Tesirine (Rova-T) Showed Overall Response Rate of 39 Percent in Pretreated Patients with Biomarker-Defined Small Cell Lung Cancer (SCLC)
      • Jun 05, 2016: OncoMed Presents Phase 1b Data on tarextumab at the 2016 ASCO Annual Meeting
      • Jun 02, 2016: Two-drug immunotherapy deemed safe for lung cancer patients, Moffitt study shows
      • May 19, 2016: Immunomedics to Report Updated Results for Sacituzumab Govitecan (IMMU-132) in Breast and Lung Cancers at Clinical Science Symposia of 2016 ASCO Annual Meeting
      • May 04, 2016: MOLOGEN to present next generation of TLR9 agonists at ASGCT 2016
      • Apr 29, 2016: Immunomedics Reports Responses With Sacituzumab Govitecan (IMMU-132) in Patients With Metastatic Solid Cancers Who Failed Prior Checkpoint-Inhibitor Therapy
      • Apr 21, 2016: OncoMed Announces Updated Phase 1b Data for Tarextumab to be Presented at the 2016 ASCO Annual Meeting
      • Apr 18, 2016: AstraZeneca Presents Data on Next-generation Investigational Wee1 Inhibitor at the AACR 2016 Annual Meeting
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Small-Cell Lung Cancer Therapeutics, Global, Clinical Trials by Region, 2016*
  • Small-Cell Lung Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Small-Cell Lung Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Small-Cell Lung Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016*
  • Small-Cell Lung Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2016*
  • Small-Cell Lung Cancer Therapeutics Clinical Trials, North America, Top Countries, 2016*
  • Small-Cell Lung Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016*
  • Small-Cell Lung Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016*
  • Proportion of Small-Cell Lung Cancer to Oncology Clinical Trials, G7 Countries (%), 2016*
  • Small-Cell Lung Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Small-Cell Lung Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Small-Cell Lung Cancer to Oncology Clinical Trials, E7 Countries (%), 2016*
  • Small-Cell Lung Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Small-Cell Lung Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Small-Cell Lung Cancer Therapeutics, Global, Clinical Trials by Phase, 2016*
  • Small-Cell Lung Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2016*
  • Small-Cell Lung Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Small-Cell Lung Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Small-Cell Lung Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Small-Cell Lung Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016*
  • Small-Cell Lung Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Small-Cell Lung Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Small-Cell Lung Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*

List of Figures

  • Small-Cell Lung Cancer Therapeutics, Global, Clinical Trials by Region (%), 2016*
  • Small-Cell Lung Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Small-Cell Lung Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Small-Cell Lung Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016*
  • Small-Cell Lung Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016*
  • Small-Cell Lung Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2016*
  • Small-Cell Lung Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016*
  • Small-Cell Lung Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016*
  • Proportion of Small-Cell Lung Cancer to Oncology Clinical Trials, G7 Countries (%), 2016*
  • Small-Cell Lung Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Small-Cell Lung Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Small-Cell Lung Cancer to Oncology Clinical Trials, E7 Countries (%), 2016*
  • Small-Cell Lung Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Small-Cell Lung Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Small-Cell Lung Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2016*
  • Small-Cell Lung Cancer Therapeutics, Global, Clinical Trials In Progress by Phase, 2016*
  • Small-Cell Lung Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Small-Cell Lung Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Small-Cell Lung Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Small-Cell Lung Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016*
  • Small-Cell Lung Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Small-Cell Lung Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Small-Cell Lung Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*
  • GlobalData Methodology
Back to Top